Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

Documenti analoghi

• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  di: Nishino, Mizuki, et al.
  Pubblicazione: (2016)
• Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: implications for targeted therapy development
  di: Lampson, Benjamin L., et al.
  Pubblicazione: (2016)
• Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2013)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  di: Nishino, Mizuki, et al.
  Pubblicazione: (2012)
• Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor
  di: Nishino, Mizuki, et al.
  Pubblicazione: (2013)